Helixbind
US-based HelixBind, founded in 2012, operates in the biotechnology sector from Worcester, Massachusetts.
Founded
2012US-based HelixBind, founded in 2012, operates in the biotechnology sector from Worcester, Massachusetts.
HelixBind, founded in 2012 and based in Worcester, Massachusetts, operates in the biotechnology sector. The company's core mission is to revolutionize the diagnosis and treatment of bloodstream infections through innovative technology. HelixBind's proprietary diagnostic platform aims to provide faster, more accurate, and detailed microbiology results, enabling clinicians to precisely identify invasive infections and tailor antimicrobial interventions for patients. Their market focus is on improving clinical outcomes and reducing healthcare costs associated with bloodstream infections.
Notable affiliated individuals and investors include experts in microbiology and biotechnology, although specific names are not provided. Key achievements include the development of their advanced diagnostic platform, which has the potential to significantly impact patient care by reducing diagnosis times and improving the accuracy of infection identification. Overall, HelixBind's contributions are poised to enhance the standard of care for bloodstream infections, offering substantial benefits to both patients and healthcare providers.
Companies similar to Helixbind include Helix BioMedix, Opsonix, Helios Innovative Technologies and ECI Biotech.
Helixbind was founded in 2012.
Helixbind's headquarters is located in Marlborough, MA, US.
Helixbind's most recent funding round was for $3M (USD) in June 2021.
As of Jun 17, 2021, Helixbind has disclosed funding of $22.7M (USD). Undisclosed round amounts are excluded.
Helixbind has 27 employees as of Feb 5, 2024.
ecibiotech.com
